2. Signaling Pathways
  3. Others
  4. Others
  5. Others Inhibitor

Others Inhibitor

Others Inhibitors (1055):

Cat. No. Product Name Effect Purity
  • HY-111374
    NMDI14
    		Inhibitor 99.37%
    NMDI14 is a nonsense mediated RNA decay (NMD) inhibitor. NMDI14 disrupts the SMG7-UPF1 interactions and inhibits NMD.
  • HY-15680
    O-Propargyl-Puromycin
    		Inhibitor 98.74%
    O-Propargyl-Puromycin, an alkyne analog of puromycin, is a potent protein synthesis inhibitor. O-Propargyl-Puromycin is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-W010342
    6-Aminonicotinamide
    		Inhibitor 99.58%
    6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP+-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (Ki=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin, in killing cancer cells.
  • HY-17511
    Potassium oxonate
    		Inhibitor 99.85%
    Potassium oxonate is an inhibitor of uricase, inhibits the phosphorylation of 5-FU to 5-fluorouridine-5'-monophosphate catalyzed by pyrimidine phosphoribosyl-transferase in a different manner from allopurinol in cell-free extracts and intact cells in vitro.
  • HY-129389
    Benzyl-α-GalNAc
    		Inhibitor 99.95%
    Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-FU (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation.
  • HY-107420
    AY 9944
    		Inhibitor 99.71%
    AY 9944 is a specific cholesterol biosynthesis inhibitor. AY 9944 inhibits the 7-dehydro cholesterol Δ7-reductase (DHCR7) enzyme with an IC50 of 13 nM. AY 9944 causes hypocholesterolemia and accumulation of 7DHC. At high doses, AY 9944 inhibits also in cultured embryos sterol Δ7-Δ8 isomerase, which causes the accumulation of cholest-8-en-3β-ol.
  • HY-139180
    PRGL493
    		Inhibitor 99.64%
    PRGL493 is a potent and selective long-chain acyl-CoA synthetase 4 (ACSL4) inhibitor. PRGL493 blocks cell proliferation and tumor growth in both breast and prostate cellular and animal models. PRGL493 is used for cancer research.
  • HY-112134
    CSN5i-3
    		Inhibitor 99.38%
    CSN5i-3 is a potent, selective and orally available inhibitor of CSN5/Jab1, and inhibits CSN-catalysed Cul1 deneddylation with an IC50 value of 5.8 nM.
  • HY-124861
    Malic enzyme inhibitor ME1
    		Inhibitor 99.53%
    Malic enzyme inhibitor ME1 (ME1; compound 1) is a potent inhibitor of Malic enzyme (ME1) with an IC50 of 0.15 μM.
  • HY-16937
    ISA-2011B
    		Inhibitor 99.97%
    ISA-2011B is a PIP5K1α inhibitor with promising anticancer effects .
  • HY-107410
    SC-26196
    		Inhibitor 99.68%
    SC-26196 is a potent, orally active Delta6 desaturase (D6D, FADS2) inhibitor (IC50=0.2 µM in a rat liver microsomal assay). Antiinflammatory properties.
  • HY-103096
    R162
    		Inhibitor 99.98%
    R162 is a potent inhibitor of glutamate dehydrogenase 1 (GDH1/GLUD1), with anti-cancer properties.
  • HY-13541
    ADH-1
    		Inhibitor 99.93%
    ADH-1, an N-cadherin antagonist, inhibits N-cadherin mediated cell adhesion.
  • HY-N0187
    4-Methylumbelliferone
    		Inhibitor 99.79%
    4-Methylumbelliferone is a hyaluronic acid biosynthesis inhibitor with antitumoral and antimetastatic effects.
  • HY-125006
    TRi-1
    		Inhibitor 99.81%
    TRi-1 is a potent, specific and irreversible inhibitor of cytosolic thioredoxin reductase 1 (TXNRD1), with an IC50 of 12 nM. TRi-1 has little mitochondrial toxicity for anticancer therapy.
  • HY-148335
    IRG1-IN-1
    		Inhibitor 99.82%
    IRG1-IN-1 is an itaconic acid derivative. IRG1-IN-1 can inhibit immune-responsive gene 1 (IRG1) activity. IRG1-IN-1 can be used for the research of cancer, inflammation and autoimmune diseases.
  • HY-131042
    NNMTi
    		Inhibitor 99.70%
    NNMTi is a potent nicotinamide N-methyltransferase (NNMT) inhibitor (IC50=1.2 μM) and selectively binds to the NNMT substrate-binding site residues. NNMTi  promotes myoblast differentiation in vitro and enhances fusion and regenerative capacity of muscle stem cells (muSCs) in aged mice.
  • HY-112721
    FDI-6
    		Inhibitor 99.65%
    FDI-6 is an inhibitor of FOXM1. FDI-6 binds directly to FOXM1 protein, to displace FOXM1 from genomic targets in MCF-7 breast cancer cells, and induce concomitant transcriptional down-regulation.
  • HY-14667
    Lomitapide
    		Inhibitor 99.60%
    Lomitapide (AEGR-733; BMS-201038) is a potent inhibitor of microsomal triglyceride-transfer protein (MTP) with an IC50 of 8 nM in vitro.
  • HY-101496
    MT-DADMe-ImmA
    		Inhibitor 98.42%
    MT-DADMe-ImmA is an inhibitor of human 5'-methylthioadenosine phosphorylase (MTAP) with a Ki of 90 pM.